Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

Abstract

A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir.

1 - 23 . (canceled) 
     
     
         24 . A method for inhibiting tumor growth in a subject comprising administering to the subject an effective amount of a cisplatin micelle wherein said cisplatin is encapsulated within the micelle in an aqueous form comprising a negatively charged phosphatidyl glycerol lipid derivative and cisplatin, wherein the molar ratio between cisplatin and the lipid derivative is 1:1 to 1:2 and an effective amount of a drug selected from the group consisting of doxorubicin, fluorodeoxyuridine, bleomycin, adriamycin, vinblastin, prednisone, vincristine and taxol. 
     
     
         25 . The method of  claim 24 , wherein the method further comprises administering an effective amount of encapsulated ganciclovir. 
     
     
         26 . The method of  claim 24  wherein the micelle further comprises encapsulated IL-2, IL-4, IL-7, IL-12, GM-CSF, IFN-gamma, TNF-alpha, RB, BRCAI, E1A, cytosine deaminase in combination with encapsulated 5-fluorocytosine, bcl-2, MDR-1, p21, p16, bax, bcl-xs, E2F, IGF-1, VEGF, or TGF-beta. 
     
     
         27 . A composition comprising a cisplatin micelle wherein the cisplatin is encapsulated within the micelle in an aqueous form comprising a negatively charged Phosphatidyl glycerol lipid derivative and cisplatin, wherein the molar ratio between cisplatin and the lipid derivative is 1:1 to 1:2 and a drug selected from the group consisting of doxorubicin, fluorodeoxyuridine, bleomycin, adriamycin, vinblastin, prednisone, vincristine and taxol. 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . The method of  claims 24  or  27 , further comprising treating the subject with an effective amount of radiation. 
     
     
         31 . The method of  claims 24  or  27 , wherein the subject is a human patient.